Compare RTX & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RTX | MRK |
|---|---|---|
| Founded | 1934 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.3B | 268.7B |
| IPO Year | 1994 | 1994 |
| Metric | RTX | MRK |
|---|---|---|
| Price | $172.65 | $111.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 17 |
| Target Price | ★ $204.25 | $125.59 |
| AVG Volume (30 Days) | 4.1M | ★ 7.3M |
| Earning Date | 04-21-2026 | 04-30-2026 |
| Dividend Yield | 1.52% | ★ 2.97% |
| EPS Growth | ★ 39.72 | 8.01 |
| EPS | 1.51 | ★ 7.28 |
| Revenue | ★ $80,738,000,000.00 | $65,011,000,000.00 |
| Revenue This Year | $6.50 | $3.61 |
| Revenue Next Year | $6.71 | $5.41 |
| P/E Ratio | $118.77 | ★ $15.78 |
| Revenue Growth | ★ 17.15 | 1.31 |
| 52 Week Low | $123.60 | $75.40 |
| 52 Week High | $214.50 | $125.14 |
| Indicator | RTX | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 23.11 | 38.35 |
| Support Level | $166.74 | $105.23 |
| Resistance Level | $180.66 | $112.44 |
| Average True Range (ATR) | 5.10 | 2.99 |
| MACD | -2.62 | -0.93 |
| Stochastic Oscillator | 0.59 | 4.70 |
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).